lucidenic acid N: from the dried fruiting bodies of Ganoderma lucidum (polyporaceae); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
lucidenic acid N : A tetracyclic triterpenoid that is 25,26,27-trinorlanost-8-en-24-oic acid substituted by hydroxy groups at positions 3 and 7 and oxo groups at positions 11 and 15 respectively (the 3beta,5alpha,7beta stereoisomer). Isolated from the fruiting bodies of Ganoderma lucidum, it exhibits cytotoxicity against tumour cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 21592283 |
| CHEMBL ID | 465487 |
| CHEBI ID | 66595 |
| SCHEMBL ID | 17312924 |
| MeSH ID | M0401988 |
| Synonym |
|---|
| lucidenic acid lm1 |
| lucidenic acid n |
| CHEMBL465487 , |
| chebi:66595 , |
| (3beta,5alpha,7beta)-3,7-dihydroxy-4,4,14-trimethyl-11,15-dioxochol-8-en-24-oic acid |
| 3,7-dihydroxy-25,26,27-trinor-11,15-dioxolanost-8-en-24-oic acid |
| bdbm50356925 |
| SCHEMBL17312924 |
| 364622-33-3 |
| lucidenic acid sp1 |
| Q27135210 |
| CS-0027823 |
| HY-N6859 |
| (4r)-4-[(3s,5r,7s,10s,13r,14r,17r)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid |
| D85039 |
| DTXSID201316785 |
| AKOS040760527 |
| lucidenic acid sp1 (lucidenic acid lm1) |
| FS-8065 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| EC 3.1.1.8 (cholinesterase) inhibitor | An EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of cholinesterase (EC 3.1.1.8). |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| tetracyclic triterpenoid | Any triterpenoid consisting of a tetracyclic skeleton. |
| cyclic terpene ketone | An alicyclic ketone in which the carbocyclic ring structure forms part of a terpene skeleton. |
| dioxo monocarboxylic acid | Any monocarboxylic acid containing two ketonic or aldehydic oxo groups. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | IC50 (µMol) | 188.3600 | 0.0000 | 1.5599 | 10.0000 | AID630340 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 (µMol) | 25.9100 | 0.0000 | 0.9332 | 10.0000 | AID630339 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID357594 | Cytotoxicity against human HepG2(2.2.15) cells | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Cytotoxicity of Ganoderma lucidum triterpenes. |
| AID502697 | Inhibition of adipogenesis in mouse 3T3L1 cells assessed as reduction of GPDH activity at 80 ug/ml after 8 days | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Lanostane triterpenes from Ganoderma lucidum suppress the adipogenesis in 3T3-L1 cells through down-regulation of SREBP-1c. |
| AID357593 | Cytotoxicity against human HepG2 cells | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Cytotoxicity of Ganoderma lucidum triterpenes. |
| AID464414 | Cytotoxicity against mouse 3T3L1 cells at 40 ug/ml after 2 days by MTT assay | 2010 | Journal of natural products, Feb-26, Volume: 73, Issue:2 | Lanostane triterpenes from the fruiting bodies of Ganoderma lucidum and their inhibitory effects on adipocyte differentiation in 3T3-L1 Cells. |
| AID357595 | Cytotoxicity against human KB cells | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Cytotoxicity of Ganoderma lucidum triterpenes. |
| AID464416 | Inhibition of adipocytes differentiation in mouse 3T3L1 cells assessed as lipid accumulation at 40 ug/ml after 8 days by Oil red O staining relative to control | 2010 | Journal of natural products, Feb-26, Volume: 73, Issue:2 | Lanostane triterpenes from the fruiting bodies of Ganoderma lucidum and their inhibitory effects on adipocyte differentiation in 3T3-L1 Cells. |
| AID357596 | Cytotoxicity against human CCM2 cells | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Cytotoxicity of Ganoderma lucidum triterpenes. |
| AID502693 | Cytotoxicity against mouse 3T3L1 cells assessed as cell viability at up to 40 ug/ml | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Lanostane triterpenes from Ganoderma lucidum suppress the adipogenesis in 3T3-L1 cells through down-regulation of SREBP-1c. |
| AID502696 | Inhibition of adipogenesis in mouse 3T3L1 cells assessed as reduction of triglyceride accumulation at 80 ug/ml after 8 days | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18 | Lanostane triterpenes from Ganoderma lucidum suppress the adipogenesis in 3T3-L1 cells through down-regulation of SREBP-1c. |
| AID630339 | Inhibition of AChE assessed as hydrolysis of acetylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum. |
| AID357597 | Cytotoxicity against mouse P388 cells | 2001 | Journal of natural products, Aug, Volume: 64, Issue:8 | Cytotoxicity of Ganoderma lucidum triterpenes. |
| AID630340 | Inhibition of BChE assessed as hydrolysis of butrylcholine preincubated for 15 mins measured after 15 mins by colorimetric Ellman assay | 2011 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21 | Selective cholinesterase inhibition by lanostane triterpenes from fruiting bodies of Ganoderma lucidum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||